CVS Health reported sales that topped Wall Street expectations on Wednesday, raised 2026 adjusted earnings guidance to at least $8.20 a share from $7.90 to $8.10, and said it will break itself in two. The stock closed more than 12% lower. Investors heard the split as the bad news, and the company’s own numbers give them a reason.
The coverage I read, from CNBC to Healthcare Dive, repeats CEO David Joyner’s line that the move comes “out of a position of strength” and quotes analysts on what it means. It never sets the plan beside the segment table or beside what Joyner said in December. The unit CVS plans to separate lifted adjusted operating income 10.6% on revenue that fell 2.0%. In December he called its stores the front door to everything else CVS sells.
What the Third-Quarter Segment Table Shows
The Pharmacy & Consumer Wellness segment, which the 10-Q says runs about 9,000 retail locations, is the closest match in the filings to the new CVS Pharmacy. The separation announcement carries no financial figures for either company, so that mapping is ours. Third quarter 2026 against third quarter 2025:
| Segment | Revenue | Adjusted operating income | Adjusted margin |
|---|---|---|---|
| Pharmacy & Consumer Wellness (stores, mail, clinics) | Down 2.0% | $1,635M vs $1,478M, up 10.6% | 4.6% vs 4.1% |
| Health Services (Caremark, Oak Street, Signify, specialty) | Up 9.5% | $2,106M vs $2,050M, up 2.7% | 3.9% vs 4.2% |
| Health Care Benefits (Aetna) | Up 2.4% | $912M vs $314M, up 190.4% | 2.5% vs 0.9% |
Add the three segments and the pharmacy unit earned $1,635 million of $4,653 million in adjusted operating income, or 35.1%, on 28.1% of segment revenue ($35,498 million of $126,317 million, before eliminations). A year earlier it earned 38.5% ($1,478 million of $3,842 million). Its share shrank because Aetna recovered, not because the pharmacies slipped.
That is the best margin of the three, earned on shrinking sales. It does not describe a business that needs releasing. The one problem the split plausibly solves sits outside the table: Leerink Partners analyst Michael Cherny said the rationale could also extend to state scrutiny of vertical integration, and Tennessee and Arkansas have passed laws that would ban common ownership of pharmacy benefit managers and pharmacies.
In December, the Pharmacies Were the Front Door
Joyner told CNBC in October 2024 that CVS was “in a turnaround” and lacked the flexibility to split. On December 11, 2025, at the company’s analyst meeting, he told Jim Cramer the retail business “becomes the front door or the gateway” into the rest of the enterprise, and that CVS would hold retail margins flat or growing. The third quarter delivered: the segment’s adjusted margin rose from 4.1% to 4.6%. The reward for hitting the target is a plan to separate the unit.
What the Announcement Leaves Out
The separation release contains no dollar figure at all. It omits:
- Pro forma earnings, revenue or debt for either company.
- A cost estimate. It names “dis-synergy costs” as a risk and attaches no number.
- A dividend amount, beyond a promise that each company will pay “an attractive dividend.”
- The terms of the commercial agreements. Joyner told analysts the benefits of owning both businesses would be “preserved in commercial agreements between the two organizations.”
The last item matters most. The 10-Q’s segment table shows intersegment eliminations, the revenue CVS’s segments book from each other and consolidation cancels, at $18,123 million for the quarter, or 16.7% of consolidated revenue ($18,123 million of $108,399 million). The table does not say how much of it crosses the new line. Whatever does stops being an internal transfer and becomes a price between two companies with separate shareholders, and that price decides which half reports the profit.
The first real numbers arrive in the Form 10 registration statement, which the release lists as a condition alongside final board approval and confirmation of tax-free treatment, with completion expected in the first half of 2028. Until that filing shows pro forma earnings, a cost estimate and the contract terms, the 12% drop is the right price for an unpriced promise. CVS should have filed the numbers first.